Difficulty: Intermediate | Prerequisites: Penicillin antibiotics study notes, Gram staining, beta-lactam MOA
This set of notes covers the remaining cell wall synthesis inhibitors beyond penicillins: cephalosporins (five generations with progressively shifting Gram-positive/Gram-negative coverage), monobactams (a niche Gram-negative-only agent), carbapenems (the broadest-spectrum beta-lactams), and vancomycin (a glycopeptide that works at a different stage of cell wall synthesis). Together with the penicillin notes, this completes the cell wall inhibitor section of antimicrobial pharmacology.
Cephalosporins trade off Gram-positive activity for Gram-negative coverage as you move from 1st to 3rd generation, with 4th generation and anti-MRSA agents restoring breadth. Monobactams (aztreonam) cover only aerobic Gram-negatives and have no penicillin cross-allergenicity. Carbapenems have the broadest beta-lactam spectrum. Vancomycin is the drug of choice for MRSA and works by inhibiting transglycosylation rather than transpeptidation.
Cephalosporin
A class of beta-lactam antibiotics with a six-membered dihydrothiazine ring fused to the beta-lactam ring. More stable than penicillins against many beta-lactamases. Think of them as the "upgraded" beta-lactams with broader and more tuneable coverage.
Cross-allergenicity
The potential for an allergic reaction to one beta-lactam class (e.g. penicillins) to carry over to another (e.g. cephalosporins). The risk is modest with cephalosporins and low with carbapenems. Aztreonam has no cross-allergenicity with penicillins.
Monobactam
A beta-lactam antibiotic with a monocyclic ring structure (four-membered ring only, no fused second ring). Aztreonam is the only clinically used monobactam.
Carbapenem
The broadest-spectrum beta-lactam class. The name refers to the carbon substitution at the C-1 position of the penam ring. In simple terms, these are the "last line" beta-lactams for serious, resistant infections.
Transglycosylation
The second stage of cell wall synthesis, where sugar units are polymerised into glycan chains. Vancomycin inhibits this step by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking both transglycosylation and subsequent cross-linking.
Ototoxicity
Damage to the inner ear causing hearing loss or tinnitus. A key adverse effect of vancomycin, particularly at high serum concentrations or in combination with other ototoxic agents (e.g. aminoglycosides).
Nephrotoxicity
Kidney damage, another significant adverse effect of vancomycin. Dosing must be individualised by weight, with intervals adjusted based on glomerular filtration rate (GFR).
Red man syndrome (infusion reaction)
A histamine-mediated reaction to rapid vancomycin infusion, characterised by flushing and a red rash over the upper body. It is not a true allergy; slowing the infusion rate typically resolves it.
Clostridioides difficile (C. diff)
An anaerobic, spore-forming bacterium that causes antibiotic-associated colitis. Third-generation cephalosporins carry the strongest association with C. diff infection among the beta-lactams.
Neurotoxicity
CNS adverse effects including seizures, confusion, or encephalopathy. Associated with carbapenems (especially imipenem, likely dose-related) and cefepime (4th-generation cephalosporin).
All cephalosporins share the beta-lactam MOA and have cross-allergenicity with penicillins. They are more stable than penicillins against beta-lactamases produced by Staphylococcus, Hemophilus, Klebsiella, and E. coli. None are active against enterococci, Listeria, or anaerobic bacteria.
The key pattern to remember: as you move from 1st to 3rd generation, Gram-positive activity decreases while Gram-negative activity increases. The 4th generation restores breadth across both.
1st Generation: Cefazolin
Spectrum: active against Gram-positive aerobic cocci; limited Gram-negative activity
Clinical use: surgical prophylaxis to prevent surgical site infections
The go-to cephalosporin for perioperative coverage
2nd Generation: Cefotetan
Spectrum: added stability against Gram-negative beta-lactamases; better coverage of H. influenzae, Moraxella catarrhalis, Klebsiella, Neisseria gonorrhoeae
Clinical uses: URI, community-acquired pneumonia (CAP), gonorrhoea, surgical prophylaxis
3rd Generation: Ceftriaxone, Ceftazidime
Spectrum: significant activity against serious Gram-negative organisms; penetrates CSF at concentrations effective for meningitis; less active against Gram-positive organisms
Ceftriaxone has the longest half-life of all cephalosporins, allowing once-daily dosing
Ceftazidime: the antipseudomonal 3rd-generation agent, used for fever in neutropenic patients and Pseudomonas aeruginosa infections
Strongest association with C. difficile infection among all cephalosporins
4th Generation: Cefepime
Spectrum: broadest of the cephalosporins, covering Pseudomonas aeruginosa and potentially more active than ceftazidime against Enterobacter species due to enhanced beta-lactamase stability
Adverse effects: cefepime-associated neurotoxicity (a specific concern with this agent)
Clinical use: nosocomial (hospital-acquired) infections
Anti-MRSA Cephalosporins (e.g. Ceftaroline)
Bind to MRSA-specific PBPs, giving activity against resistant Gram-positive pathogens: MRSA, vancomycin-resistant S. aureus (VRSA), vancomycin-insensitive S. aureus (VISA), and hetero-resistant VISA (hVISA)
Approved for acute bacterial skin and skin-structure infections and CAP
Considered a last-resort option
Drug: Aztreonam
Structure: Four-membered monocyclic beta-lactam ring (no fused second ring).
Spectrum of activity
Limited to susceptible aerobic Gram-negative organisms only: Pseudomonas, most Gram-negative rods
No Gram-positive or anaerobic activity whatsoever
Mechanism of action
Non-penicillin beta-lactam; binds PBPs on Gram-negative bacteria to inhibit cell wall synthesis.
Key advantage
No cross-allergenicity with penicillin. This makes aztreonam a safe option for patients with a confirmed penicillin or other beta-lactam allergy who need Gram-negative coverage.
Clinical pearl: Aztreonam fills a specific niche. When a patient has a beta-lactam allergy and you need to cover Gram-negatives (including Pseudomonas), aztreonam is your agent.
Drugs: Imipenem, Meropenem, Ertapenem
Why carbapenems are distinctive among beta-lactams
Broadest spectrum of all beta-lactam drugs: aerobic Gram-positive, Gram-negative, and some anaerobic activity
More efficient penetration through the bacterial cell wall
Resistance to most bacterial beta-lactamases
High affinity for all bacterial PBPs
Mechanism of action
Same beta-lactam MOA: inhibit PBP-mediated cross-linking of peptidoglycan, leading to autolysis and cell death.
Adverse effects
Pharmacologic: CNS effects including seizures (likely dose-related, most associated with imipenem)
Intolerance: nausea, vomiting, constipation, diarrhoea (NVCD)
Allergic: low risk of cross-reaction with penicillin allergy (can generally be used in patients with non-severe penicillin allergy)
Clinical pearl: Carbapenems are reserved for serious, resistant infections precisely because of their broad spectrum. Overuse drives carbapenem-resistant organisms, which are extremely difficult to treat.
Drug: Vancomycin
Spectrum of activity
Gram-positive organisms not susceptible to other beta-lactam antibiotics
Covers: MSSA, MRSA, streptococci, C. difficile
Poor activity against Gram-negative organisms
Mechanism of action
Vancomycin binds to the D-Ala-D-Ala terminus of peptidoglycan precursor units in the bacterial cell wall and inhibits transglycosylation (the second stage of cell wall synthesis). Beta-lactams inhibit the third stage (transpeptidation). The combined result is prevention of cross-linking and alteration of cell wall permeability, leading to cell death.
Adverse effects
Pharmacologic: ototoxicity, renal toxicity (nephrotoxicity)
Intolerance: infusion reactions, including red man syndrome (histamine-mediated flushing with rapid infusion)
Idiosyncratic: haematologic reactions
Allergic: can be used in patients allergic to penicillin (no structural cross-reactivity)
Key pharmacokinetic points
Doses must be individualised: dosed by weight, with the interval determined by GFR
Oral vancomycin absorption is negligible; oral administration is used only for GI infections (specifically C. difficile colitis)
IV vancomycin is needed for systemic infections
Drug of choice for MRSA. This is the single most important clinical fact about vancomycin for exam purposes.
Students often think higher-generation cephalosporins are "better" overall. They are not. Higher generations gain Gram-negative coverage at the cost of Gram-positive activity (until the 4th generation restores breadth). Each generation has its niche.
A frequent mistake is assuming oral vancomycin treats systemic infections. Oral vancomycin has negligible absorption and is effective only for GI infections, particularly C. difficile colitis. Systemic MRSA infections require IV vancomycin.
Students sometimes conflate red man syndrome with a true vancomycin allergy. Red man syndrome is a histamine-mediated infusion reaction, not an immune-mediated allergy. Slowing the infusion rate is the fix, not discontinuing the drug.
Another common error is thinking aztreonam covers Gram-positive organisms. It has zero Gram-positive or anaerobic activity. Its entire value is Gram-negative coverage in patients with beta-lactam allergies.
The cephalosporin generation trade-off (Gram-positive decreases, Gram-negative increases from 1st to 3rd) is a guaranteed exam concept.
3rd-generation cephalosporins have the strongest association with C. difficile infection. Expect questions linking antibiotic use to pseudomembranous colitis.
Cefepime neurotoxicity is a specific 4th-generation adverse effect worth remembering separately from the general beta-lactam profile.
Aztreonam's lack of penicillin cross-allergenicity is a classic exam question. If the stem describes a penicillin-allergic patient needing Gram-negative coverage, aztreonam is likely the answer.
Vancomycin dosing is individualised (by weight, interval by GFR). Questions may test whether you know to adjust the interval (not just the dose) based on renal function.
Vancomycin's mechanism (inhibits transglycosylation, i.e. the 2nd stage) differs from beta-lactams (inhibit transpeptidation, i.e. the 3rd stage). Exams may ask you to distinguish these two stages.
Carbapenems have the broadest beta-lactam spectrum but carry a seizure risk (especially imipenem). This adverse-effect pairing is commonly tested.
True or False: 1st-generation cephalosporins have better Gram-negative coverage than 3rd-generation. (False)
Fill in the blank: The cephalosporin generation most strongly associated with C. difficile infection is the ______ generation. (3rd)
True or False: Aztreonam has cross-allergenicity with penicillin. (False)
Fill in the blank: Vancomycin inhibits ______, the second stage of cell wall synthesis. (transglycosylation)
True or False: Oral vancomycin is appropriate for treating MRSA bacteraemia. (False, IV is required)
Q: A patient is scheduled for elective surgery. Which cephalosporin is most commonly used for surgical prophylaxis?
A: Cefazolin (1st generation). It provides good Gram-positive coverage against skin flora likely to cause surgical site infections.
Q: A neutropenic patient develops fever. Cultures grow Pseudomonas aeruginosa. Which cephalosporin covers this organism?
A: Ceftazidime (3rd generation, antipseudomonal) or cefepime (4th generation). Both cover Pseudomonas.
Q: How does vancomycin's mechanism of action differ from that of beta-lactam antibiotics?
A: Vancomycin inhibits transglycosylation (the 2nd stage of cell wall synthesis) by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors. Beta-lactams inhibit transpeptidation (the 3rd stage) by binding to PBPs.
Q: A patient with a severe penicillin allergy has a serious Pseudomonas infection. Which agent can be used without cross-allergenicity risk?
A: Aztreonam. It is a monobactam with no cross-allergenicity to penicillins and covers aerobic Gram-negative organisms including Pseudomonas.
Q: Why must vancomycin dosing intervals be adjusted based on GFR?
A: Vancomycin is renally cleared. In patients with reduced GFR, the drug accumulates, increasing the risk of nephrotoxicity and ototoxicity. Extending the dosing interval prevents toxic trough levels.
This material connects directly to the penicillins study notes, which cover the foundational beta-lactam MOA and the four penicillin subclasses. Understanding why penicillins fail (beta-lactamase destruction, altered PBPs) explains why each of these agents was developed.
C. difficile infection links to GI pharmacology and infectious disease: antibiotic-associated colitis is a clinical consequence of disrupting normal gut flora, and oral vancomycin is one of the primary treatments.
The concept of antibiotic stewardship connects here: carbapenems and anti-MRSA cephalosporins are reserved agents precisely because overuse drives resistance, which ties into microbiology and public health.
Cephalosporin, cefazolin, cefotetan, ceftriaxone, ceftazidime, cefepime, ceftaroline, 1st generation, 2nd generation, 3rd generation, 4th generation, anti-MRSA cephalosporin, monobactam, aztreonam, carbapenem, imipenem, meropenem, ertapenem, glycopeptide, vancomycin, transglycosylation, transpeptidation, PBP, cell wall synthesis, cross-allergenicity, C. difficile, pseudomembranous colitis, red man syndrome, ototoxicity, nephrotoxicity, neurotoxicity, cefepime neurotoxicity, surgical prophylaxis, nosocomial infection, empiric therapy, MRSA, MSSA, VRSA, VISA, hVISA, GFR-based dosing, antimicrobial pharmacology, PHAR 101